Thermo Fisher Scientific announced today that it plans to invest an additional $2 billion in the U.S. over the next four years. The company said its investment should strengthen American innovation, manufacturing and economic competitiveness in the life sciences sector. It also comes as a number of companies consider investing in U.S. infrastructure amid potential…
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
Fujifilm Diosynth Biotechnologies, a major contract development and manufacturing organization (CDMO), has entered into a 10-year manufacturing supply agreement with Regeneron Pharmaceuticals, valued at over $3 billion. The deal has the Fujifilm subsidiary providing U.S.-based manufacturing for Regeneron, with planned expansions at Fujifilm’s large-scale biopharmaceutical manufacturing facility in Holly Springs, North Carolina. The Holly Springs…
Bayer invests $44M in Pennsylvania manufacturing plant
Bayer announced today that it opened a 70,000-square-foot expansion at its Myerstown, Pennsylvania, facility. The grand opening of the state-of-the-art facility follows a $44 million investment in 2022. Bayer says it reflects its commitment to providing self-care solutions to consumers across North America while advancing meaningful engagement with the local community. This facility in Myerstown…
Novartis to expand U.S. manufacturing, R&D footprint with $23B investment
Novartis announced today that it plans to invest $23 billion over five years to expand its U.S.-based infrastructure. The company said its investment aims to ensure all key Novartis medicines for U.S. patients will be made in the U.S. Its financial commitment enables the company to expand on its current pharmaceutical manufacturing, research and technology…
BDD Pharma opens new GMP manufacturing plant
BDD announced today that it opened a new 122-square-meter GMP manufacturing facility at BioCity near Glasgow. The company opened its facility after two years of development following a successful inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) last month. A £2 million funding round from existing investors facilitated the development of the state-of-the-art…
Ashland expands pharmaceutical tablet coating plant in Brazil
Ashland announced that it completed a $10 million expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil. The company plans to mark the occasion with a ribbon-cutting ceremony tomorrow, April 4. This investment significantly expands Ashland’s pharmaceutical footprint in the region and capabilities to meet increasing market demand for coated tablets in Latin America and…
Seamless scaling: The role of smart automation in CGT manufacturing
Cell and gene therapy teams face unique challenges in scaling production while maintaining precision and compliance. Strategic automation enables seamless technology transfer, integration, and scalability—turning solutions to reduce complexity into a competitive advantage. Advanced therapeutics is one of the fastest growing areas in life sciences. Many of today’s most promising new treatments are cell and…
Qosina, AdvantaPure collaborate on pharmaceutical manufacturing
Qosina announced today that it entered into a collaboration with AdvantaPure to enhance its selection of solutions for pharmaceutical manufacturing. AdvantaPure, the high-purity products division of NewAge Industries, anticipates and satisfies the evolving needs of the pharmaceutical and biopharmaceutical manufacturing industries. As an official distribution partner for AdvantaPure, Qosina now expands its tubing portfolio with…
How Cegeka tackles GxP validation in pharmaceutical ERP projects
Dominique De Vos, Global Solution Manager Pharma & Life Sciences at Cegeka has an equation to make sense of digital transformation in the pharma landscape and beyond. NO + OT = CNO. In other words, “New Organization plus Old Technology equals Costly New Organization.” The equation is a reminder that legacy systems are often incompatible…
Merck KGaA Q&A: Solving pharma’s ‘make’ step with SYNTHIA AI synthesis planning
The buzz around AI in drug discovery often centers on generating new molecular ideas. But as computational chemists know, an in silico design is only valuable if it can be efficiently synthesized in the lab and is manufacturable after that. Merck KGaA, Darmstadt, Germany, with its roots in both chemistry (via Sigma-Aldrich) and life science…